Stocksigma LogoStocksigma Logo

Glenmark Pharma Alliance IGI Submits US FDA IND for ISB 2301

Glenmark Pharmaceuticals announced that Ichnos Glenmark Innovation (IGI) submitted an Investigational New Drug (IND) application to the US FDA on 17th

Glenmark Pharma Alliance IGI Submits US FDA IND for ISB 2301

Glenmark Pharmaceuticals Ltd 路 Press Release 路 18 Nov 2026, 1:05 am

Glenmark Pharma Alliance IGI Submits US FDA IND for ISB 2301 Glenmark Pharmaceuticals announced that Ichnos Glenmark Innovation (IGI) submitted an Investigational New Drug (IND) application to the US FDA on 17th Nov'26 for ISB 2301. ISB 2301 is a first-in-class pentaspecific immune cell activator targeting solid tumors, engineered using IGI's BEAT platform to target three tumor-associated antigens and engage T cells and NK cells. Preclinical studies demonstrated favorable pharmacokinetic and tolerability profiles in non-human primates. IGI plans to commence Phase 1 clinical trials in patients with solid tumors in 2027.

Original exchange filing (PDF)

More announcements from Glenmark Pharmaceuticals Ltd

All Glenmark Pharmaceuticals Ltd announcements